MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1823239 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.8%
TTM net income YoY45.8%
TTM EPS YoY47.6%
Revenue 3-yr CAGR-20.2%
Net income 3-yr CAGR—
Margins
Gross margin39.1%
Operating margin-45.4%
Net margin-30.8%
FCF margin-5.9%
EBITDA margin-35.1%
Returns
ROE-29.8%
ROA-9.1%
ROIC (approx.)-27.0%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets43.3%
Debt / equity0.75x
Current ratio4.66x
Interest coverage-4.57x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $45.85M | $51.44M | $65.84M | $49.87M | $41.63M | $47.40M | $46.85M | $56.41M |
| Cost of revenue | $29.66M | $30.79M | $32.14M | $37.02M | $35.98M | $39.63M | $39.12M | $37.44M |
| Gross profit | $16.19M | $20.65M | $33.70M | $12.84M | $5.66M | $7.77M | $7.72M | $19.39M |
| R&D expense | $3.39M | $3.70M | $3.89M | $3.79M | $3.84M | $4.88M | $4.89M | $4.56M |
| SG&A expense | $30.50M | $32.07M | $29.09M | $31.58M | $35.46M | $38.72M | $39.56M | $41.24M |
| Operating income | -$20.62M | -$15.09M | -$2.16M | -$58.80M | -$41.03M | -$66.28M | -$49.16M | -$38.13M |
| Interest expense | $4.03M | $4.81M | $5.75M | $6.55M | $6.84M | $6.82M | $6.78M | $11.26M |
| Pretax income | -$24.07M | -$21.80M | -$6.53M | -$63.01M | -$45.15M | -$74.12M | -$52.69M | -$46.07M |
| Income tax | -$75,000 | -$171,000 | -$151,000 | $6,000 | -$92,000 | -$4.29M | $162,000 | -$7,000 |
| Net income | -$13.84M | -$12.42M | -$3.73M | -$35.68M | -$25.56M | -$39.59M | -$29.95M | -$26.14M |
| EBITDA | -$14.88M | -$9.78M | $2.74M | -$52.86M | -$35.06M | -$60.32M | -$43.47M | -$32.66M |
| EPS (basic) | -0.09 | -0.08 | -0.02 | — | -0.18 | -0.27 | -0.21 | — |
| EPS (diluted) | -0.09 | -0.08 | -0.02 | — | -0.18 | -0.27 | -0.21 | — |
| Weighted avg. shares (diluted) | 149.07M | 148.00M | 146.43M | — | 144.68M | 144.24M | 143.43M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $73.02M | $70.09M | $165.92M | $216.89M | $243.57M | $269.91M | $285.05M | $322.40M |
| Receivables | $25.71M | $31.14M | $33.41M | $25.50M | $22.54M | $27.88M | $28.49M | $38.52M |
| Inventory | $43.25M | $41.23M | $40.46M | $40.49M | $45.33M | $46.67M | $49.77M | $50.08M |
| Current assets | $154.00M | $155.66M | $251.74M | $296.25M | $325.87M | $359.76M | $376.28M | $429.15M |
| PP&E, net | $135.67M | $142.41M | $146.93M | $151.48M | $158.62M | $162.73M | $166.43M | $164.47M |
| Goodwill | $129.43M | $129.43M | $129.43M | $129.43M | $129.43M | $129.43M | $159.88M | $159.88M |
| Intangibles | $130.97M | $138.38M | $144.89M | $151.54M | $185.88M | $193.07M | $199.58M | $194.96M |
| Total assets | $600.07M | $603.75M | $713.22M | $770.58M | $849.19M | $896.97M | $959.75M | $1.01B |
| Current liabilities | $33.06M | $38.42M | $42.62M | $44.92M | $61.57M | $69.68M | $63.16M | $56.97M |
| Short-term debt | $1.50M | $1.12M | $5.44M | $5.44M | $5.44M | $5.44M | $5.44M | $5.44M |
| Long-term debt | $145.68M | $145.98M | $235.57M | $286.33M | $287.38M | $288.44M | $289.50M | $290.49M |
| Total debt | $147.18M | $147.10M | $241.01M | $291.77M | $292.82M | $293.88M | $294.94M | $295.93M |
| Total liabilities | $259.90M | $248.16M | $344.13M | $397.87M | $417.33M | $428.98M | $429.48M | $431.04M |
| Shareholders' equity | $195.89M | $204.62M | $211.56M | $212.38M | $245.44M | $265.86M | $300.61M | $325.29M |
| Net debt | $74.16M | $77.01M | $75.09M | $74.88M | $49.25M | $23.97M | $9.89M | -$26.47M |
| Cash flow statement | ||||||||
| Operating cash flow | $5.01M | $3.99M | $8.66M | -$22.77M | -$15.15M | -$10.27M | -$9.39M | -$14.64M |
| Capital expenditure | $523,000 | $370,000 | $4.44M | $2.11M | $2.93M | $2.87M | $4.50M | $5.85M |
| Free cash flow | $4.49M | $3.62M | $4.23M | -$24.88M | -$18.08M | -$13.14M | -$13.89M | -$20.49M |
| Investing cash flow | -$523,000 | -$370,000 | -$4.44M | -$2.11M | -$2.93M | -$3.24M | -$23.13M | -$4.93M |
| Financing cash flow | -$1.57M | -$98.98M | -$55.23M | -$1.82M | -$8.25M | -$1.53M | -$4.90M | -$236.19M |
| Depreciation & amortization | $5.74M | $5.31M | $4.90M | $5.93M | $5.97M | $5.96M | $5.69M | $5.47M |
| Stock-based compensation | $10.12M | $10.21M | $6.74M | $3.93M | $9.06M | $6.79M | $10.40M | $10.54M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.